Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 41 of 143 for:    NIFEDIPINE

Comparison of Tab.Labetalol and Tab.Nifedipine for Management of Postpartum Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02426177
Recruitment Status : Unknown
Verified April 2015 by fariha javed, Dow University of Health Sciences.
Recruitment status was:  Not yet recruiting
First Posted : April 24, 2015
Last Update Posted : April 24, 2015
Sponsor:
Information provided by (Responsible Party):
fariha javed, Dow University of Health Sciences

Brief Summary:
To compare effectiveness of oral labetalol and oral nifedipine for management of postpartum hypertension.

Condition or disease Intervention/treatment Phase
Postnatal Hypertension Drug: Labetalol Drug: Nifedipine Phase 3

Detailed Description:
A comparison of oral labetalol and oral nifedipine for management of postpartum hypertension. Which drug is more effective in lowering blood pressures in patient with postpartum hypertension.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 98 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Comparison of Oral Labetalol and Oral Nifedipine for Postpartum Hypertension Management
Study Start Date : May 2015
Estimated Primary Completion Date : May 2016
Estimated Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Postpartum Care

Arm Intervention/treatment
Active Comparator: group A
tab.labetalol is given to the patient with postpartum hypertension in dose of 100 mg 6 hourly increased to maximum 600 mg in 24 hours
Drug: Labetalol
anti-hypertensive agents

Active Comparator: group B
tab.nifedipine is given to the patient with postpartum hypertension in the dose of 10 mg twice a day to maximum dose of 60 mg per 24 hours
Drug: Nifedipine
calcium channel blocker ,for lowering blood pressure




Primary Outcome Measures :
  1. Blood Pressure less than 140/90 mm of hg [ Time Frame: 24 hours ]
    less than 140/90 mm of hg



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 48 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • all women with postpartum hypertension as a continuation of pregnancy induced hypertension,eclampsia, pre-eclampsia or new onset de-novo postpartum hypertension,of any parity.
  • age group between 18-48.
  • after informed consent.

Exclusion Criteria:

  • all women with chronic hypertension, uncontrolled and un treated medical disorders will be excluded.
  • conditions in which drugs labetalol and nifedipine is contraindicated.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02426177


Contacts
Layout table for location contacts
Contact: fariha javed, mbbs 923009298708 farihajaved207@yahoo.com

Sponsors and Collaborators
Dow University of Health Sciences
Investigators
Layout table for investigator information
Principal Investigator: fariha javed, mbbs Dow University of Health Sciences

Layout table for additonal information
Responsible Party: fariha javed, resident, Dow University of Health Sciences
ClinicalTrials.gov Identifier: NCT02426177     History of Changes
Other Study ID Numbers: DowUHS
First Posted: April 24, 2015    Key Record Dates
Last Update Posted: April 24, 2015
Last Verified: April 2015
Keywords provided by fariha javed, Dow University of Health Sciences:
postpartum hypertension
labetalol in postpartum hypertension
nifedipine in postpartum hypertension
Additional relevant MeSH terms:
Layout table for MeSH terms
Nifedipine
Hypertension
Vascular Diseases
Cardiovascular Diseases
Labetalol
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Antihypertensive Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists